TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
TScan Therapeutics, Inc.NASDAQ: TCRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $693K rose 2.2% year over year, ahead of the -18.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.1% from the prior quarter. Over 3 fiscal years it compounded at -17.7% a year.
Context
- Depreciation & amortization amounted to 27.8% of revenue in FY2025, down 118.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2.2% holds above the trailing-twelve-month pace of -18.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.87M USD
- Year-over-year change
- -30.2%
- 4-year CAGR
- -3.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.87M | -30.2% |
| FY2024 | 2024-12-31 | 4.11M | -23.4% |
| FY2023 | 2023-12-31 | 5.36M | +4.4% |
| FY2022 | 2022-12-31 | 5.14M | +54.4% |
| FY2021 | 2021-12-31 | 3.33M | — |
Depreciation & Amortization vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's LTM Mar 2026 depreciation & amortization of $2.88M is the 4th largest of the 10 companies compared; the peer median is $1.21M.
- Its year-over-year change of -18.4% is the 6th highest of 9, against a peer median of -11.7%.
- Depreciation & amortization amounts to 31.5% of revenue for TCRX, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.74M | -13.3% | +13.9% | 3.0% | |
| LTM Mar 2026 | $5.17M | +4.4% | -20.7% | 7.8% | |
| LTM Mar 2026 | $3.86M | -37.8% | -3.9% | — | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.58M | -10.2% | -13.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.21M | +8.3% | +36.2% | — |
| LTM Apr 2026 | $170.49K | -37.6% | -19.3% | 9.5% | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $131K | -84.0% | -41.1% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding TCRX) | $1.21M | -11.7% | -8.7% | 7.8% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| Deferred Income Tax | (9.16M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.52M | 4.55M | 5.21M | 9.55M | 11.71M |
| Change in Working Capital | (5.9M) | (10.23M) | 17.61M | 5.05M | (18.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10K | 528K | (52K) | 1.99M | (3.01M) |
| Other Working Capital | (5.91M) | (10.76M) | 17.66M | 3.06M | (15.17M) |
| Other Non-Cash Items | 9.16M | 260K | (315K) | (2.03M) | (1.95M) |
| Operating Cash Flow | (48.68M) | (66.5M) | (61.36M) | (110.82M) | (135.32M) |
| Capital Expenditures | (9.94M) | (4.23M) | (3.15M) | (3.83M) | (4.41M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (77.61M) | (241.45M) | (87.47M) |
| Sales of Investments | 0 | 0 | 20M | 192.66M | 201.25M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (9.94M) | (4.23M) | (60.76M) | (52.61M) | 109.37M |
| Debt Repayment | 0 | 29.35M | 0 | 15.31M | 0 |
| Common Stock Issued | 89.65M | 193K | 42.41M | 33.13M | 264K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 291K | (191K) | 93.03M | 160.32M | (600K) |
| Financing Cash Flow | 189.67M | 29.36M | 135.44M | 208.77M | (336K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 131.05M | (41.37M) | 13.33M | 45.33M | (26.28M) |
| Free Cash Flow | (58.62M) | (70.73M) | (64.5M) | (114.65M) | (139.73M) |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.